Covered recipient · General Payments record
GEORGE DUVALL
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$3,143.01
154 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,143.01 | 154 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie Inc. | $1,353.62 | 67 |
| PFIZER INC. | $410.13 | 16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $372.36 | 26 |
| Takeda Pharmaceuticals U.S.A., Inc. | $318.57 | 15 |
| GENZYME CORPORATION | $177.78 | 8 |
| Janssen Biotech, Inc. | $157.63 | 8 |
| AstraZeneca Pharmaceuticals LP | $149.00 | 3 |
| Medtronic, Inc. | $47.78 | 1 |
| Celgene Corporation | $40.34 | 3 |
| Ardelyx, Inc. | $33.70 | 2 |
| Lilly USA, LLC | $18.17 | 1 |
| Fresenius Kabi USA, LLC | $18.11 | 1 |
| Braintree Laboratories, Inc. | $17.24 | 1 |
| RedHill Biopharma Inc. | $15.44 | 1 |
| Evoke Pharma, Inc. | $13.14 | 1 |
Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GEORGE DUVALL
NPI 1073526604 · CMS profile ID 138834
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
TYLER, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1073526604?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GEORGE DUVALL, NPI 1073526604, CMS profile ID 138834. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073526604?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). GEORGE DUVALL, NPI 1073526604, CMS profile ID 138834. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073526604?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- GEORGE DUVALL, NPI 1073526604, CMS profile ID 138834, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1073526604?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
154 matching records · $3,143.01 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 154.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $18.19 | 04/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988429387 | CMS |
| AbbVie Inc. | $14.70 | 04/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773591 | CMS |
| AbbVie Inc. | $26.86 | 04/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773579 | CMS |
| AbbVie Inc. | $26.85 | 04/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773583 | CMS |
| AbbVie Inc. | $59.41 | 04/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773573 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.24 | 04/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057355899 | CMS |
| AbbVie Inc. | $18.75 | 04/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773563 | CMS |
| AbbVie Inc. | $11.74 | 04/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773569 | CMS |
| GENZYME CORPORATION | $22.02 | 03/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049610135 | CMS |
| Braintree Laboratories, Inc. | $17.24 | 03/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006444555 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $10.16 | 03/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057488123 | CMS |
| AbbVie Inc. | $28.83 | 03/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773559 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $5.73 | 03/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055381713 | CMS |
| AbbVie Inc. | $6.44 | 03/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773555 | CMS |
| Medtronic, Inc. | $47.78 | 03/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1018963891 | CMS |
| AbbVie Inc. | $23.02 | 03/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773549 | CMS |
| PFIZER INC. | $12.16 | 03/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049553625 | CMS |
| Ardelyx, Inc. | $17.59 | 03/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1052945475 | CMS |
| AbbVie Inc. | $16.09 | 03/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773539 | CMS |
| AbbVie Inc. | $16.09 | 03/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773543 | CMS |
| Janssen Biotech, Inc. | $16.08 | 03/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988429373 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1.06 | 03/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055381709 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.99 | 03/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055381711 | CMS |
| PFIZER INC. | $11.48 | 03/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049404543 | CMS |
| Celgene Corporation | $13.16 | 03/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016361037 | CMS |
| Janssen Biotech, Inc. | $11.41 | 03/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988429365 | CMS |
| AbbVie Inc. | $16.07 | 02/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773529 | CMS |
| AbbVie Inc. | $16.07 | 02/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773533 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $9.69 | 02/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057248849 | CMS |
| RedHill Biopharma Inc. | $15.44 | 02/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996663457 | CMS |
| PFIZER INC. | $11.12 | 02/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049618701 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $24.24 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055381707 | CMS |
| AbbVie Inc. | $12.09 | 02/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773523 | CMS |
| Janssen Biotech, Inc. | $25.25 | 02/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988429357 | CMS |
| PFIZER INC. | $9.30 | 02/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049629583 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.95 | 02/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057087263 | CMS |
| AbbVie Inc. | $6.67 | 02/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773519 | CMS |
| AbbVie Inc. | $23.75 | 02/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773515 | CMS |
| Evoke Pharma, Inc. | $13.14 | 01/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056621867 | CMS |
| PFIZER INC. | $9.37 | 01/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049148283 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12.11 | 01/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057349057 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.14 | 01/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057443109 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.95 | 01/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057489329 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $2.21 | 01/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055381703 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.71 | 01/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055381705 | CMS |
| AbbVie Inc. | $15.67 | 01/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773509 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $9.69 | 01/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057267179 | CMS |
| AbbVie Inc. | $29.67 | 01/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773499 | CMS |
| AbbVie Inc. | $29.67 | 01/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996773505 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12.65 | 01/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057347735 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $4,098,178.59 | 730 |
| PY2024 | Recipient | $1,328.99 | 7 |
| PY2024 | Principal investigator | $5,038,555.15 | 1,258 |
| PY2023 | Recipient | $519.93 | 1 |
| PY2023 | Principal investigator | $3,649,653.73 | 557 |
| PY2022 | Principal investigator | $1,811,459.74 | 284 |
| PY2021 | Recipient | $1,545.44 | 1 |
| PY2021 | Principal investigator | $1,226,332.53 | 150 |
| PY2020 | Recipient | $17,842.00 | 2 |
| PY2020 | Principal investigator | $873,043.80 | 191 |
| PY2019 | Recipient | $33,437.88 | 3 |
| PY2019 | Principal investigator | $714,998.19 | 138 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
730 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Eli Lilly and Company | $25,389.50 | 12/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE AND OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187893640 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 12/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175288759 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 12/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175290192 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 12/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175290369 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 12/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175290803 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,084.00 | 12/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis? | No dispute reported | 06/30/2026 | 1175411467 |
| Principal investigator 1 | Janssen Research & Development, LLC | $76.00 | 12/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175287909 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,937.00 | 12/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288434 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,687.00 | 12/26/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175411516 |
| Principal investigator 1 | PFIZER INC. | $1,173.00 | 12/23/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228813098 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,000.00 | 12/22/2025 | Non-covered Recipient Entity Tyler Research Institute Llc | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype | No dispute reported | 06/30/2026 | 1226121389 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $176.00 | 12/19/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674501 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $11,165.00 | 12/19/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674509 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $194.00 | 12/19/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674511 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $9,011.00 | 12/19/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674524 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,185.00 | 12/19/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674540 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $414.00 | 12/19/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674545 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 12/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288385 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 12/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288500 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 12/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288508 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 12/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289178 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 12/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289215 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 12/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289426 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 12/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289825 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 12/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290159 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 12/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290177 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 12/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290470 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 12/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290756 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 12/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290872 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $373.00 | 12/19/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223289938 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $135.00 | 12/19/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223289940 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $8,564.40 | 12/18/2025 | Non-covered Recipient Entity Tyler Research Institute | A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. | No dispute reported | 06/30/2026 | 1235992845 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 12/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288130 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 12/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288247 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 12/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288276 |
| Principal investigator 1 | Janssen Research & Development, LLC | $335.00 | 12/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288683 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 12/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289142 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 12/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289625 |
| Principal investigator 1 | ABBVIE INC. | $1,096.80 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202526848 |
| Principal investigator 1 | ABBVIE INC. | $2,782.00 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202526860 |
| Principal investigator 1 | ABBVIE INC. | $3,090.77 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) | No dispute reported | 06/30/2026 | 1202527684 |
| Principal investigator 1 | ABBVIE INC. | $2,600.00 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202527884 |
| Principal investigator 1 | ABBVIE INC. | $1,755.00 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202527886 |
| Principal investigator 1 | ABBVIE INC. | $5,267.70 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202527888 |
| Principal investigator 1 | ABBVIE INC. | $2,494.70 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) | No dispute reported | 06/30/2026 | 1202527890 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $909.00 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674497 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,242.00 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674505 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $720.00 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674515 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $194.00 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674520 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,963.00 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674528 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $686.00 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674531 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $414.00 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674537 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $4,001.00 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674542 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $8,337.00 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674548 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $878.00 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674551 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $949.55 | 12/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279 CD/UC Ph2 OLE | No dispute reported | 06/30/2026 | 1223289196 |
| Principal investigator 1 | ABBVIE INC. | $13,571.15 | 12/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202526386 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175287924 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288139 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288155 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288313 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288539 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288731 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288752 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,729.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288844 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288953 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288960 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289019 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,729.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289052 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289255 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,729.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289278 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289324 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289346 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289369 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289419 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289456 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289495 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289676 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 11/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290057 |
| Principal investigator 1 | ABBVIE INC. | $894.90 | 11/25/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202525242 |
| Principal investigator 1 | Genentech, Inc. | $42,171.00 | 11/25/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674701 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $373.00 | 11/25/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223288761 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,984.25 | 11/25/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223288763 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $67.50 | 11/25/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223288765 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $25,192.35 | 11/25/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223288767 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $85.00 | 11/24/2025 | Non-covered Recipient Entity Tyler Research Institute Llc | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype | No dispute reported | 06/30/2026 | 1226121379 |
| Principal investigator 1 | ABBVIE INC. | $5,456.90 | 11/21/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202525104 |
| Principal investigator 1 | ABBVIE INC. | $10,632.80 | 11/21/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202525106 |
| Principal investigator 1 | Genentech, Inc. | $690.00 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674704 |
| Principal investigator 1 | Genentech, Inc. | $1,089.00 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674722 |
| Principal investigator 1 | Genentech, Inc. | $414.00 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674776 |
| Principal investigator 1 | Genentech, Inc. | $117.00 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674782 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674802 |
| Principal investigator 1 | Genentech, Inc. | $9,660.00 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674833 |
| Principal investigator 1 | Genentech, Inc. | $7,998.00 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674838 |
| Principal investigator 1 | Genentech, Inc. | $5,575.00 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674851 |
| Principal investigator 1 | Genentech, Inc. | $255.00 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674860 |
| Principal investigator 1 | Genentech, Inc. | $117.00 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674868 |
| Principal investigator 1 | Genentech, Inc. | $329.00 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674880 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,888.76 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223288605 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $44.55 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223288621 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $393.96 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223288623 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,077.00 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223288625 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $262.54 | 11/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223288627 |
| Principal investigator 1 | PFIZER INC. | $584.00 | 11/17/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228812401 |
| Principal investigator 1 | PFIZER INC. | $2,471.00 | 11/17/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228812500 |
| Principal investigator 1 | PFIZER INC. | $584.00 | 11/17/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228812511 |
| Principal investigator 1 | Genentech, Inc. | $17,738.00 | 11/14/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674697 |
| Principal investigator 1 | ABBVIE INC. | $7,545.60 | 11/13/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202524187 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $100,790.10 | 11/10/2025 | Non-covered Recipient Entity Tyler Research Institute, LLC | A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) | No dispute reported | 06/30/2026 | 1244052569 |
| Principal investigator 1 | Genentech, Inc. | $558.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674679 |
| Principal investigator 1 | Genentech, Inc. | $117.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674686 |
| Principal investigator 1 | Genentech, Inc. | $690.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674690 |
| Principal investigator 1 | Genentech, Inc. | $819.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674694 |
| Principal investigator 1 | Genentech, Inc. | $9,660.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674709 |
| Principal investigator 1 | Genentech, Inc. | $576.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674712 |
| Principal investigator 1 | Genentech, Inc. | $576.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674717 |
| Principal investigator 1 | Genentech, Inc. | $2,361.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674724 |
| Principal investigator 1 | Genentech, Inc. | $1,452.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674729 |
| Principal investigator 1 | Genentech, Inc. | $264.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674732 |
| Principal investigator 1 | Genentech, Inc. | $1,656.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674735 |
| Principal investigator 1 | Genentech, Inc. | $88.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674739 |
| Principal investigator 1 | Genentech, Inc. | $288.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674743 |
| Principal investigator 1 | Genentech, Inc. | $927.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674747 |
| Principal investigator 1 | Genentech, Inc. | $414.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674750 |
| Principal investigator 1 | Genentech, Inc. | $19,993.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674754 |
| Principal investigator 1 | Genentech, Inc. | $414.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674757 |
| Principal investigator 1 | Genentech, Inc. | $6,914.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674762 |
| Principal investigator 1 | Genentech, Inc. | $720.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674766 |
| Principal investigator 1 | Genentech, Inc. | $176.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674769 |
| Principal investigator 1 | Genentech, Inc. | $1,518.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674787 |
| Principal investigator 1 | Genentech, Inc. | $1,085.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674790 |
| Principal investigator 1 | Genentech, Inc. | $117.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674794 |
| Principal investigator 1 | Genentech, Inc. | $720.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674798 |
| Principal investigator 1 | Genentech, Inc. | $1,407.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674805 |
| Principal investigator 1 | Genentech, Inc. | $9,660.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674809 |
| Principal investigator 1 | Genentech, Inc. | $10,322.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674813 |
| Principal investigator 1 | Genentech, Inc. | $1,133.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674818 |
| Principal investigator 1 | Genentech, Inc. | $966.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674822 |
| Principal investigator 1 | Genentech, Inc. | $1,756.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674825 |
| Principal investigator 1 | Genentech, Inc. | $19,320.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674829 |
| Principal investigator 1 | Genentech, Inc. | $662.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674840 |
| Principal investigator 1 | Genentech, Inc. | $5,455.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674845 |
| Principal investigator 1 | Genentech, Inc. | $219.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674857 |
| Principal investigator 1 | Genentech, Inc. | $519.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674865 |
| Principal investigator 1 | Genentech, Inc. | $369.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674872 |
| Principal investigator 1 | Genentech, Inc. | $9,971.00 | 11/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674877 |
| Principal investigator 1 | ABBVIE INC. | $13,398.75 | 11/06/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202523521 |
| Principal investigator 1 | ABBVIE INC. | $10,099.35 | 11/05/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202522893 |
| Principal investigator 1 | ABBVIE INC. | $8,106.35 | 11/05/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) | No dispute reported | 06/30/2026 | 1202522959 |
| Principal investigator 1 | Genentech, Inc. | $144.00 | 11/05/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | vixarelimab ulcerative colitis study | No dispute reported | 06/30/2026 | 1211674884 |
| Principal investigator 1 | Genentech, Inc. | $11,527.00 | 11/05/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | vixarelimab ulcerative colitis study | No dispute reported | 06/30/2026 | 1211674890 |
| Principal investigator 1 | ABBVIE INC. | $1,096.80 | 11/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202520283 |
| Principal investigator 1 | ABBVIE INC. | $9,306.10 | 11/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202521147 |
| Principal investigator 1 | ABBVIE INC. | $4,050.00 | 11/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202521149 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,937.00 | 11/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289779 |
| Principal investigator 1 | Janssen Research & Development, LLC | $76.00 | 11/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289787 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,780.00 | 11/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175411436 |
| Principal investigator 1 | ABBVIE INC. | $13,398.75 | 10/30/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202519727 |
| Principal investigator 1 | Genentech, Inc. | $144.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674579 |
| Principal investigator 1 | Genentech, Inc. | $117.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674581 |
| Principal investigator 1 | Genentech, Inc. | $117.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674584 |
| Principal investigator 1 | Genentech, Inc. | $10,011.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674587 |
| Principal investigator 1 | Genentech, Inc. | $10,329.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674592 |
| Principal investigator 1 | Genentech, Inc. | $9,660.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674597 |
| Principal investigator 1 | Genentech, Inc. | $276.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674601 |
| Principal investigator 1 | Genentech, Inc. | $234.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674612 |
| Principal investigator 1 | Genentech, Inc. | $8,002.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674621 |
| Principal investigator 1 | Genentech, Inc. | $552.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674627 |
| Principal investigator 1 | Genentech, Inc. | $432.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674630 |
| Principal investigator 1 | Genentech, Inc. | $117.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674635 |
| Principal investigator 1 | Genentech, Inc. | $414.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674639 |
| Principal investigator 1 | Genentech, Inc. | $288.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674643 |
| Principal investigator 1 | Genentech, Inc. | $117.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674648 |
| Principal investigator 1 | Genentech, Inc. | $15,961.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674655 |
| Principal investigator 1 | Genentech, Inc. | $9,660.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674670 |
| Principal investigator 1 | Genentech, Inc. | $288.00 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674674 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,246.19 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223287715 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,481.92 | 10/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223287717 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175287939 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175287954 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288000 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,937.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288054 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288269 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288370 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288410 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175288446 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288601 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175288633 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288722 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288774 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288914 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289404 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,340.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175289699 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289758 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289795 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,889.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289811 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289879 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175289933 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289975 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290088 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290110 |
| Principal investigator 1 | Janssen Research & Development, LLC | $76.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290140 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175290212 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290235 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175290406 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290462 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290531 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175290554 |
| Principal investigator 1 | Janssen Research & Development, LLC | $76.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290702 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290733 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175290817 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 10/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290920 |
| Principal investigator 1 | ABBVIE INC. | $13,398.75 | 10/23/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202518261 |
| Principal investigator 1 | ABBVIE INC. | $12,982.95 | 10/23/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) | No dispute reported | 06/30/2026 | 1202518277 |
| Principal investigator 1 | ABBVIE INC. | $91,800.00 | 10/23/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202518279 |
| Principal investigator 1 | Genentech, Inc. | $24,106.00 | 10/23/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674661 |
| Principal investigator 1 | PFIZER INC. | $593.00 | 10/20/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228812371 |
| Principal investigator 1 | PFIZER INC. | $4,040.00 | 10/20/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228812504 |
| Principal investigator 1 | PFIZER INC. | $4,436.00 | 10/20/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228812517 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,661.03 | 10/16/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279 CD/UC Ph2 OLE | No dispute reported | 06/30/2026 | 1223287031 |
| Principal investigator 1 | ABBVIE INC. | $1,057.50 | 10/09/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202514461 |
| Principal investigator 1 | ABBVIE INC. | $879.60 | 10/09/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202515579 |
| Principal investigator 1 | ABBVIE INC. | $19,775.30 | 10/09/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202515739 |
| Principal investigator 1 | Genentech, Inc. | $4,518.00 | 10/09/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674652 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,063.50 | 10/09/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223286597 |
| Principal investigator 1 | Genentech, Inc. | $34,280.00 | 10/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674606 |
| Principal investigator 1 | Genentech, Inc. | $3,728.00 | 10/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674666 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,553.00 | 10/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175411505 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175287991 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288081 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288257 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288307 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288377 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288523 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288782 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289287 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289309 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289487 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289604 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289671 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289715 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289892 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289967 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290243 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290426 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 09/29/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290477 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,075.00 | 09/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175411447 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $35,558.10 | 09/25/2025 | Non-covered Recipient Entity Tyler Research Institute, LLC | A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) | No dispute reported | 06/30/2026 | 1244052567 |
| Principal investigator 1 | ABBVIE INC. | $13,398.75 | 09/18/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202511430 |
| Principal investigator 1 | ABBVIE INC. | $40,196.25 | 09/18/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202511464 |
| Principal investigator 1 | ABBVIE INC. | $13,398.75 | 09/18/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202511466 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $102,664.00 | 09/18/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674416 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,380.00 | 09/18/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674426 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $9,777.00 | 09/18/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674434 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,359.00 | 09/18/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674446 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,152.00 | 09/18/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674449 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $513.00 | 09/18/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674462 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,242.00 | 09/18/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674487 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $28,980.00 | 09/18/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674491 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $909.00 | 09/18/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674494 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,532.01 | 09/18/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223285656 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,096.00 | 09/18/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223285658 |
| Principal investigator 1 | Janssen Research & Development, LLC | $76.00 | 09/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290132 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,937.00 | 09/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290500 |
| Principal investigator 1 | Janssen Research & Development, LLC | $76.00 | 09/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290642 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,937.00 | 09/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290655 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,576.00 | 09/15/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175411511 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $11,445.00 | 09/12/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674430 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,346.00 | 09/12/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674438 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $58,662.00 | 09/12/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674458 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,726.00 | 09/12/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674478 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,506.00 | 09/12/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674483 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,031.75 | 09/12/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223285337 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $18,800.10 | 09/09/2025 | Non-covered Recipient Entity Tyler Research Institute, LLC | A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) | No dispute reported | 06/30/2026 | 1244052565 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,909.00 | 09/08/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175411479 |
| Principal investigator 1 | ABBVIE INC. | $17,850.00 | 09/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) | No dispute reported | 06/30/2026 | 1202509168 |
| Principal investigator 1 | ABBVIE INC. | $26,797.50 | 09/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202509170 |
| Principal investigator 1 | ABBVIE INC. | $2,494.70 | 09/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) | No dispute reported | 06/30/2026 | 1202507759 |
| Principal investigator 1 | ABBVIE INC. | $4,426.40 | 09/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202507761 |
| Principal investigator 1 | ABBVIE INC. | $2,988.00 | 09/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202508098 |
| Principal investigator 1 | PFIZER INC. | $8,872.00 | 09/03/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228826918 |
| Principal investigator 1 | ABBVIE INC. | $13,398.75 | 08/28/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202506383 |
| Principal investigator 1 | ABBVIE INC. | $26,797.50 | 08/28/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202506385 |
| Principal investigator 1 | ABBVIE INC. | $53,223.75 | 08/28/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202506387 |
| Principal investigator 1 | ABBVIE INC. | $13,398.75 | 08/28/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202506393 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175287984 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,729.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288070 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288262 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288335 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288440 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288532 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288586 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288648 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288741 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288829 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288923 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,729.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289038 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289077 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289199 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289221 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,729.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289228 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,889.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289237 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289685 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289707 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289834 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289840 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289848 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289863 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289900 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289925 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290013 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290022 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290035 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290096 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290145 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290200 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290398 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290487 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290547 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290562 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290586 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290595 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290618 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290647 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290719 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290727 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290778 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,729.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290839 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290864 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 08/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290938 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $10,836.00 | 08/26/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674472 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,303.64 | 08/26/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223284587 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,250.00 | 08/25/2025 | Non-covered Recipient Entity Tyler Research Institute Llc | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype | No dispute reported | 06/30/2026 | 1226121287 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,026.00 | 08/21/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674421 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,394.77 | 08/21/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223284497 |
| Principal investigator 1 | Eli Lilly and Company | $21,938.21 | 08/15/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | AN ADAPTIVE, DOSE-RANGING, PHASE 2 STUDY OF ELTREKIBART GIVEN ALONE OR IN COMBINATION WITH MIRIKIZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187891468 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $28,507.00 | 08/14/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674469 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,970.00 | 08/11/2025 | Non-covered Recipient Entity Tyler Research Institute Llc | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype | No dispute reported | 06/30/2026 | 1226121276 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $949.55 | 08/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279 CD/UC Ph2 OLE | No dispute reported | 06/30/2026 | 1223283943 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,859.05 | 08/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223283945 |
| Principal investigator 1 | ABBVIE INC. | $7,600.80 | 08/05/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202501538 |
| Principal investigator 1 | ABBVIE INC. | $2,494.70 | 08/05/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) | No dispute reported | 06/30/2026 | 1202501718 |
| Principal investigator 1 | ABBVIE INC. | $17,346.70 | 08/05/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202501720 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,525.00 | 08/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175411522 |
| Principal investigator 1 | ABBVIE INC. | $12,723.75 | 07/31/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202500780 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $80,690.00 | 07/31/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211674442 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $37,469.00 | 07/31/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674466 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,286.47 | 07/31/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223283276 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,905.00 | 07/31/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223283278 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $373.00 | 07/31/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223283280 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 07/30/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175288356 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 07/30/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175288852 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,629.00 | 07/30/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175290913 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 07/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175287894 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 07/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288148 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 07/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288321 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 07/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288516 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 07/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288994 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 07/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289070 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 07/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289540 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 07/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289739 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 07/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289911 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 07/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290081 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,230.00 | 07/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290711 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 07/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290742 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 07/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290793 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $39,570.00 | 07/22/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674475 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,918.42 | 07/22/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279 CD/UC Ph2 OLE | No dispute reported | 06/30/2026 | 1223282884 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,859.05 | 07/22/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223282886 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,804.95 | 07/17/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223282746 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,804.95 | 07/17/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223282748 |
| Principal investigator 1 | PFIZER INC. | $1,747.00 | 07/11/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228826924 |
| Principal investigator 1 | PFIZER INC. | $584.00 | 07/11/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228826931 |
| Principal investigator 1 | PFIZER INC. | $2,471.00 | 07/11/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228827802 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $28,090.00 | 07/10/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674454 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,079.00 | 07/10/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223282508 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,481.92 | 07/10/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223282510 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $28,948.50 | 07/10/2025 | Non-covered Recipient Entity Tyler Research Institute, LLC | A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) | No dispute reported | 06/30/2026 | 1244052563 |
| Principal investigator 1 | ABBVIE INC. | $16,692.75 | 07/08/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202497140 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,281.00 | 07/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175411411 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,031.75 | 07/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223282222 |
| Principal investigator 1 | ABBVIE INC. | $7,029.10 | 07/02/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) | No dispute reported | 06/30/2026 | 1202494693 |
| Principal investigator 1 | ABBVIE INC. | $10,804.70 | 07/02/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202494695 |
| Principal investigator 1 | ABBVIE INC. | $4,680.65 | 07/02/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202494699 |
| Principal investigator 1 | ABBVIE INC. | $7,450.00 | 07/02/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202496309 |
| Principal investigator 1 | ABBVIE INC. | $112.20 | 07/02/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202496311 |
| Principal investigator 1 | ABBVIE INC. | $13,315.85 | 07/02/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202496315 |
| Principal investigator 1 | Genentech, Inc. | $348.00 | 07/02/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | vixarelimab ulcerative colitis study | No dispute reported | 06/30/2026 | 1211674574 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,629.00 | 06/30/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175288063 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,340.00 | 06/30/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175288907 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 06/30/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175289104 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 06/30/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175289120 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 06/30/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175289870 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 06/30/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175290351 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288047 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288111 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288180 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288285 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288675 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288814 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289062 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289184 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289302 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,632.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289464 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289548 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289731 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,953.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289961 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290005 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290050 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290516 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,632.00 | 06/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290930 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,109.14 | 06/24/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223281740 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,031.75 | 06/24/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223281742 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,079.00 | 06/24/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223281794 |
| Principal investigator 1 | Genentech, Inc. | $24,353.00 | 06/19/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674568 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,165.93 | 06/19/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279 CD/UC Ph2 OLE | No dispute reported | 06/30/2026 | 1223281624 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,859.05 | 06/19/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223281654 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288038 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288199 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,230.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288456 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288593 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288668 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288947 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289096 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289192 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289340 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289513 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289917 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290074 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,230.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290334 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290455 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290762 |
| Principal investigator 1 | PFIZER INC. | $2,471.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228829516 |
| Principal investigator 1 | PFIZER INC. | $1,747.00 | 06/18/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228829858 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $949.55 | 06/12/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279 CD/UC Ph2 OLE | No dispute reported | 06/30/2026 | 1223281112 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $31,325.40 | 06/12/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223281114 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,079.00 | 06/12/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223281174 |
| Principal investigator 1 | Eli Lilly and Company | $1,014.78 | 06/10/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187893638 |
| Principal investigator 1 | PFIZER INC. | $1,173.00 | 06/09/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228829279 |
| Principal investigator 1 | ABBVIE INC. | $5,955.80 | 06/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202488621 |
| Principal investigator 1 | ABBVIE INC. | $318.50 | 06/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) | No dispute reported | 06/30/2026 | 1202488623 |
| Principal investigator 1 | ABBVIE INC. | $1,588.80 | 06/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202489763 |
| Principal investigator 1 | ABBVIE INC. | $3,398.40 | 06/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202489765 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $261,501.30 | 06/03/2025 | Non-covered Recipient Entity Tyler Research Institute, LLC | A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) | No dispute reported | 06/30/2026 | 1244052561 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 05/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288103 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 05/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288208 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 05/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288219 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 05/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288623 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 05/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288937 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 05/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288971 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 05/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289245 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 05/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289503 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,729.00 | 05/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290604 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 05/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290662 |
| Principal investigator 1 | Genentech, Inc. | $17,066.00 | 05/27/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674564 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,696.00 | 05/26/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175411460 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,770.00 | 05/23/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175411430 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,457.00 | 05/22/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223280134 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,303.64 | 05/22/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223280136 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,576.00 | 05/19/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175411442 |
| Principal investigator 1 | Genentech, Inc. | $18,112.00 | 05/15/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674571 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,896.10 | 05/15/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223279830 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,488.75 | 05/15/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223279832 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,288.40 | 05/13/2025 | Non-covered Recipient Entity Tyler Research Institute, LLC | A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) | No dispute reported | 06/30/2026 | 1244052559 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 05/12/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175287961 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 05/12/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288608 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 05/12/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288616 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 05/12/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289159 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 05/12/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289523 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 05/12/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290205 |
| Principal investigator 1 | Janssen Research & Development, LLC | $335.00 | 05/12/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290786 |
| Principal investigator 1 | Genentech, Inc. | $14,908.00 | 05/08/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211674560 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,303.64 | 05/08/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223279168 |
| Principal investigator 1 | ABBVIE INC. | $2,360.00 | 05/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202482837 |
| Principal investigator 1 | ABBVIE INC. | $52,500.35 | 05/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202482839 |
| Principal investigator 1 | Celgene Corporation | $4,922.00 | 05/07/2025 | Non-covered Recipient Entity Tyler Research Institute | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. | No dispute reported | 06/30/2026 | 1222307173 |
| Principal investigator 1 | ABBVIE INC. | $282.50 | 05/06/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202481485 |
| Principal investigator 1 | ABBVIE INC. | $17,454.90 | 05/06/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202481487 |
| Principal investigator 1 | ABBVIE INC. | $18,883.90 | 05/06/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202481491 |
| Principal investigator 1 | ABBVIE INC. | $2,787.20 | 05/06/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) | No dispute reported | 06/30/2026 | 1202481493 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $130,467.70 | 05/01/2025 | Non-covered Recipient Entity Tyler Research Institute, LLC | A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) | No dispute reported | 06/30/2026 | 1244052537 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175287947 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288097 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288122 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288162 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288172 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288203 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288392 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288400 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288492 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,632.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288660 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288766 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288869 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288875 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288979 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288987 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,953.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289003 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289011 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289127 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289150 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289395 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,228.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289412 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289530 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289566 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,228.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289571 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289660 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289723 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289762 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,228.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289856 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289988 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,632.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290029 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290043 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290065 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290116 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290228 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290287 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290308 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290377 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290390 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290447 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290508 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290770 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,729.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290882 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290904 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,506.00 | 04/28/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175411473 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,079.00 | 04/28/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223278684 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,394.77 | 04/23/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223278590 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/21/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175288087 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/21/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175288225 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 04/21/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175289361 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/21/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175290281 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 04/21/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175290634 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,240.00 | 04/17/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175411491 |
| Principal investigator 1 | PFIZER INC. | $1,502.00 | 04/11/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228829910 |
| Principal investigator 1 | PFIZER INC. | $4,373.00 | 04/11/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228830025 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,394.77 | 04/08/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223277640 |
| Principal investigator 1 | ABBVIE INC. | $7,326.00 | 04/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202468950 |
| Principal investigator 1 | ABBVIE INC. | $13,571.60 | 04/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202469148 |
| Principal investigator 1 | ABBVIE INC. | $263.70 | 04/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202469152 |
| Principal investigator 1 | ABBVIE INC. | $2,949.70 | 04/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) | No dispute reported | 06/30/2026 | 1202469619 |
| Principal investigator 1 | ABBVIE INC. | $54,504.30 | 04/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202469623 |
| Principal investigator 1 | ABBVIE INC. | $1,248.75 | 04/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202469631 |
| Principal investigator 1 | ABBVIE INC. | $4,491.30 | 04/03/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202469635 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,575.00 | 03/31/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175411423 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,152.00 | 03/31/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175411454 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,142.00 | 03/27/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175411485 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 03/25/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288483 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 03/25/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288579 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 03/25/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288807 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,557.00 | 03/25/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288931 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 03/25/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289262 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 03/25/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289980 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 03/25/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290125 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 03/25/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290170 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 03/25/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290626 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 03/25/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290685 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 03/25/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290833 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 03/25/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290847 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,425.14 | 03/25/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223276979 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,151.25 | 03/25/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223276981 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,079.00 | 03/25/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223277009 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 03/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175287901 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 03/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288191 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 03/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288416 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 03/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289166 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 03/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289353 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 03/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289596 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 03/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289884 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,228.00 | 03/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290152 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 03/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290571 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,729.00 | 03/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290610 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 03/24/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290857 |
| Principal investigator 1 | PFIZER INC. | $584.00 | 03/21/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228831614 |
| Principal investigator 1 | PFIZER INC. | $584.00 | 03/21/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228831759 |
| Principal investigator 1 | PFIZER INC. | $584.00 | 03/21/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228832605 |
| Principal investigator 1 | PFIZER INC. | $584.00 | 03/21/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228832698 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,654.00 | 03/20/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175288347 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,937.00 | 03/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288008 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,362.00 | 03/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289641 |
| Principal investigator 1 | Janssen Research & Development, LLC | $76.00 | 03/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290693 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,362.00 | 03/19/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290823 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,087.15 | 03/19/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223276781 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,017.05 | 03/19/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223276795 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $14,589.90 | 03/13/2025 | Non-covered Recipient Entity Tyler Research Institute, LLC | A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) | No dispute reported | 06/30/2026 | 1244052557 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,286.47 | 03/11/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223276161 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,952.25 | 03/11/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223276163 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,800.00 | 03/10/2025 | Non-covered Recipient Entity Tyler Research Institute Llc | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype | No dispute reported | 06/30/2026 | 1226121201 |
| Principal investigator 1 | ABBVIE INC. | $21,941.80 | 03/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202459455 |
| Principal investigator 1 | ABBVIE INC. | $2,025.00 | 03/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202459518 |
| Principal investigator 1 | ABBVIE INC. | $6,975.85 | 03/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202462044 |
| Principal investigator 1 | Genentech, Inc. | $396.00 | 03/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | vixarelimab ulcerative colitis study | No dispute reported | 06/30/2026 | 1211674553 |
| Principal investigator 1 | ABBVIE INC. | $26,122.50 | 03/06/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202456629 |
| Principal investigator 1 | ABBVIE INC. | $11,830.00 | 03/06/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202458290 |
| Principal investigator 1 | ABBVIE INC. | $21,202.40 | 03/06/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202458692 |
| Principal investigator 1 | Eli Lilly and Company | $43,060.00 | 03/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE | No dispute reported | 06/30/2026 | 1187893210 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,970.00 | 03/04/2025 | Non-covered Recipient Entity Tyler Research Institute Llc | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype | No dispute reported | 06/30/2026 | 1226121197 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,481.92 | 03/04/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223275925 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175287932 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175287967 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175287975 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288363 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288475 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,229.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288573 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,229.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288789 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,229.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288836 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289027 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289087 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289111 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,229.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289434 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289446 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,229.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289588 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289747 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289770 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289803 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290182 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290220 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290253 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,228.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290264 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290320 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290329 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290524 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,229.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290897 |
| Principal investigator 1 | PFIZER INC. | $584.00 | 03/03/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228831664 |
| Principal investigator 1 | Janssen Research & Development, LLC | $159.00 | 02/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288689 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 02/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289386 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 02/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289652 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 02/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290104 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 02/28/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290298 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,500.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175287917 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288032 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288232 |
| Principal investigator 1 | Janssen Research & Development, LLC | $335.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288240 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288293 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288301 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288341 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288423 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288466 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288554 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288640 |
| Principal investigator 1 | Janssen Research & Development, LLC | $117.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288698 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288704 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288714 |
| Principal investigator 1 | Janssen Research & Development, LLC | $124.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288799 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288894 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288902 |
| Principal investigator 1 | Janssen Research & Development, LLC | $76.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289269 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289295 |
| Principal investigator 1 | Janssen Research & Development, LLC | $335.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289315 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289330 |
| Principal investigator 1 | Janssen Research & Development, LLC | $836.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289377 |
| Principal investigator 1 | Janssen Research & Development, LLC | $124.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289480 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289558 |
| Principal investigator 1 | Janssen Research & Development, LLC | $335.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289581 |
| Principal investigator 1 | Janssen Research & Development, LLC | $335.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289633 |
| Principal investigator 1 | Janssen Research & Development, LLC | $124.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289691 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175289996 |
| Principal investigator 1 | Janssen Research & Development, LLC | $335.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290270 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290361 |
| Principal investigator 1 | Janssen Research & Development, LLC | $335.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290383 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290576 |
| Principal investigator 1 | Janssen Research & Development, LLC | $335.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290669 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290677 |
| Principal investigator 1 | Janssen Research & Development, LLC | $335.00 | 02/26/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290810 |
| Principal investigator 1 | Eli Lilly and Company | $550.48 | 02/25/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE | No dispute reported | 06/30/2026 | 1187891892 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,343.25 | 02/25/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223275509 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,801.00 | 02/25/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223275511 |
| Principal investigator 1 | Genentech, Inc. | $17,544.00 | 02/21/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | vixarelimab ulcerative colitis study | No dispute reported | 06/30/2026 | 1211674556 |
| Principal investigator 1 | ABBVIE INC. | $13,745.40 | 02/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202453230 |
| Principal investigator 1 | ABBVIE INC. | $40,196.25 | 02/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202453234 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,764.55 | 02/18/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223275355 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 02/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288019 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 02/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288562 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 02/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288861 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 02/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290343 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 02/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290433 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,415.00 | 02/17/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290749 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,500.00 | 02/13/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223275247 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $48,167.05 | 02/07/2025 | Non-covered Recipient Entity Tyler Research Institute | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | No dispute reported | 06/30/2026 | 1235992841 |
| Principal investigator 1 | ABBVIE INC. | $1,752.50 | 02/06/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202449731 |
| Principal investigator 1 | ABBVIE INC. | $29,224.85 | 02/06/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202449736 |
| Principal investigator 1 | ABBVIE INC. | $675.00 | 02/06/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202449770 |
| Principal investigator 1 | ABBVIE INC. | $7,022.60 | 02/05/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202444485 |
| Principal investigator 1 | ABBVIE INC. | $10,519.60 | 02/05/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202446102 |
| Principal investigator 1 | ABBVIE INC. | $5,281.90 | 02/05/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M20-259 - Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) | No dispute reported | 06/30/2026 | 1202446154 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,864.50 | 02/05/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223274761 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,817.10 | 02/05/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223274779 |
| Principal investigator 1 | PFIZER INC. | $584.00 | 02/03/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228831749 |
| Principal investigator 1 | PFIZER INC. | $1,173.00 | 02/03/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228831767 |
| Principal investigator 1 | PFIZER INC. | $2,471.00 | 02/03/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228832104 |
| Principal investigator 1 | PFIZER INC. | $1,173.00 | 02/03/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228832198 |
| Principal investigator 1 | PFIZER INC. | $1,173.00 | 02/03/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228832541 |
| Principal investigator 1 | PFIZER INC. | $584.00 | 02/03/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228832599 |
| Principal investigator 1 | PFIZER INC. | $1,173.00 | 02/03/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228832692 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,425.00 | 01/31/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175411496 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 01/30/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175289044 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 01/30/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175289818 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 01/30/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175289954 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 01/30/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175290539 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 01/30/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175290954 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,063.50 | 01/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223274527 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,583.25 | 01/29/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223274537 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 01/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175288546 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,532.00 | 01/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289134 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,229.00 | 01/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289207 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 01/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175289944 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,632.00 | 01/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290416 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 01/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290441 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 01/27/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175290494 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,250.00 | 01/27/2025 | Non-covered Recipient Entity Tyler Research Institute Llc | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype | No dispute reported | 06/30/2026 | 1226121193 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,031.75 | 01/21/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223274243 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,048.00 | 01/20/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175411416 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,079.00 | 01/17/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223274015 |
| Principal investigator 1 | ABBVIE INC. | $3,685.50 | 01/16/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M20-259 - Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) | No dispute reported | 06/30/2026 | 1202439523 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,937.00 | 01/15/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175288822 |
| Principal investigator 1 | Janssen Research & Development, LLC | $76.00 | 01/15/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175290945 |
| Principal investigator 1 | PFIZER INC. | $11,454.60 | 01/15/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228831754 |
| Principal investigator 1 | Janssen Research & Development, LLC | $217.00 | 01/13/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175288330 |
| Principal investigator 1 | Janssen Research & Development, LLC | $445.00 | 01/13/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175289617 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 01/13/2025 | Non-covered Recipient Entity Tyler Rsrch Inst Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175290890 |
| Principal investigator 1 | Eli Lilly and Company | $10,050.00 | 01/10/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB | No dispute reported | 06/30/2026 | 1187891466 |
| Principal investigator 1 | ABBVIE INC. | $13,398.75 | 01/09/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202437814 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,402.75 | 01/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223273627 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,825.60 | 01/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223273645 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,873.00 | 01/07/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223273647 |
| Principal investigator 1 | PFIZER INC. | $443.00 | 01/06/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228831670 |
| Principal investigator 1 | PFIZER INC. | $730.00 | 01/06/2025 | Non-covered Recipient Entity Tyler Research Institute LLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228832203 |
| Principal investigator 1 | ABBVIE INC. | $3,645.30 | 01/02/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202434137 |
| Principal investigator 1 | ABBVIE INC. | $1,539.30 | 01/02/2025 | Non-covered Recipient Entity TYLER RESEARCH INSTITUTE LLC | M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202435845 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $21,398.10 | 01/01/2025 | Non-covered Recipient Entity Tyler Research Institute | A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1235992843 |